ClinicalTrials.gg
RecruitingNCT06967311Updated Jun 15, 2025

Human and Microbial Determinants of the Onset of IBD Flares

An observational study in IBD (Inflammatory Bowel Disease), sponsored by Viome. Recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-15.

Sponsored by Viome · Observational

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Inflammatory Bowel Diseases with a site in Brazil — 8 open to participants now, 9 under way, 4 of them phase 3. Inflammatory Bowel Diseases · Brazil.

Started
2025
with 1 other
Observational
2 of 19
1 open now
Registered
17th of 19
by date

Among the 19 studies in Inflammatory Bowel Diseases with a site in Brazil, this one is one of 2 that started in 2025, is one of 2 observational ones, and was the 17th registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

8 of the 19 studies in Inflammatory Bowel Diseases with a site in Brazil are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Inflammatory Bowel Diseases with a site in Brazil, or all of them as a file.
02

Study summary

This study will collect longitudinal biological samples and survey data to identify the triggers of IBD flares.

Read the detailed description

This is a longitudinal observational study whose goals are to identify:

Microbial and human molecular triggers of IBD relapses, Microbial and human molecular pathways strongly associated with flares that could be targeted with nutrition with a therapeutic potential, Biomarkers of IBD for Dx purposes, Identify microbial functions associated with release of BH4.

03

Conditions studied

  • IBD (Inflammatory Bowel Disease)

Keywords

  • observational
  • IBD
  • microbiome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults diagnosed with Crohn's Disease or Ulcerative Colitis that are patients at Universidade Federal de Santa Catarina (UFSC) Hospital and under care of Dr. Vivian Menegassi

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient at Universidade Federal de Santa Catarina (UFSC) Hospital, under care of Dr. Vivian Menegassi

Exclusion criteria

Exclusion Criteria:

  • Cancer Diagnosis/Treatment
  • Under 18 years old
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Inflammatory Bowel Disease (IBD)

    Individuals diagnosed with IBD

06

What researchers measure

Primary outcomes

  1. Stool microbial KEGG orthologs (KOs) associated with IBD

    Metatranscriptomic tests will be used to quantify microbial KOs in stool samples. At the end of the study, we will use machine learning to identify KOs whose expression is associated with IBD.

    Time frame: For 12 months from enrollment

07

Study locations

1 of 1 sites recruiting
  • LABOX, Department of Biochemistry, Universidade Federal de Santa Catarina
    Florianópolis, Santa Catarina 88037-100, Brazil
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Feb 2030, 61 months after the start.

Of 37 industry-sponsored observational studies under Inflammatory Bowel Diseases, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 44. This study's planned 61 months is above that.

Counting every sponsor, half of 281 studies reached it within 36 months; a quarter within 20 and three quarters within 122.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2025
First posted
May 13, 2025
StartActual
Jan 31, 2025
Primary completionEst.
Feb 2030
CompletionEst.
Feb 2030
Last update
Jun 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06967311
Lead sponsor
Viome
Collaborators
Universidade Federal de Santa Catarina
Responsible party
Sponsor
First posted
May 13, 2025
Start date
Jan 31, 2025
Primary completion
Feb 2030 (estimated)
Completion
Feb 2030 (estimated)
Last update
Jun 15, 2025

Study contacts

Raquel Clinical Research Coordinator
Contact
studies@viome.com
425-368-5248
Momo Vuyisich Chief Science Officer, PhD
Contact
studies@viome.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion